Clearmind Medicine Announces First US Site For Phase I/IIa Clinical Trial Evaluating CMND-100 In Patients With Alcohol Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine has announced its first US site for a Phase I/IIa clinical trial evaluating CMND-100 in patients with alcohol use disorder.
May 22, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine's announcement of the first US site for the Phase I/IIa clinical trial of CMND-100 may positively impact the company's stock.
The announcement of the first US site for the Phase I/IIa clinical trial of CMND-100 is a significant milestone for Clearmind Medicine. This development may attract investor interest and positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100